{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:35:46Z","timestamp":1783110946158,"version":"3.54.6"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82102496"],"award-info":[{"award-number":["82102496"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172034"],"award-info":[{"award-number":["82172034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81770096"],"award-info":[{"award-number":["81770096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical trials on icotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), have shown promising results as targeted therapy for non-small cell lung cancer (NSCLC). This study aimed to establish an effective scoring system to predict the one-year progression-free survival (PFS) of advanced NSCLC patients with EGFR mutations treated with icotinib as targeted therapy. A total of 208 consecutive patients with advanced EGFR-positive NSCLC treated with icotinib were enrolled in this study. Baseline characteristics were collected within 30 days before icotinib treatment. PFS was taken as the primary endpoint and the response rate as the secondary endpoint. Least absolute shrinkage and selection operator (LASSO) regression analysis and Cox proportional hazards regression analysis were used to select the optimal predictors. We evaluated the scoring system using a five-fold cross-validation. PFS events occurred in 175 patients, with a median PFS of 9.9 months (interquartile range, 6.8-14.5). The objective response rate (ORR) was 36.1%, and the disease control rate (DCR) was 67.3%. The final ABC-Score consisted of three predictors: age, bone metastases and carbohydrate antigen 19-9 (CA19-9). Upon comparison of all three factors, the combined ABC-score (area under the curve (AUC)= 0.660) showed a better predictive accuracy than age (AUC = 0.573), bone metastases (AUC = 0.615), and CA19-9 (AUC = 0.608) individually. A five-fold cross-validation showed good discrimination with AUC = 0.623. The ABC-score developed in this study was significantly effective as a prognostic tool for icotinib in advanced NSCLC patients with EGFR mutations.<\/jats:p>","DOI":"10.1007\/s10637-023-01329-8","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T10:02:34Z","timestamp":1683194554000},"page":"463-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognosis prediction of icotinib as targeted therapy for advanced EGFR-positive non\u2013small cell lung cancer patients"],"prefix":"10.1007","volume":"41","author":[{"given":"Xueyun","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daquan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"1329_CR1","unstructured":"NCCN clinical practice guidelines In oncology for non-small cell lung cancer. Version 1.2022 (https:\/\/www.nccn.org)"},{"issue":"9","key":"1329_CR2","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1200\/JCO.20.03570","volume":"39","author":"NH Hanna","year":"2021","unstructured":"Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM et al (2021) Therapy for Stage IV Non-Small-Cell Lung Cancer with driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin oncology: official J Am Soc Clin Oncol 39(9):1040\u20131091","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"34","key":"1329_CR3","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","volume":"33","author":"K Kelly","year":"2015","unstructured":"Kelly K, Altorki NK, Eberhardt WE, O\u2019Brien ME, Spigel DR, Crin\u00f2 L et al (2015) Adjuvant Erlotinib Versus Placebo in patients with Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): a Randomized, Double-Blind, phase III trial. J Clin oncology: official J Am Soc Clin Oncol 33(34):4007\u20134014","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"1329_CR4","doi-asserted-by":"crossref","unstructured":"Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y et al (2016) First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.The Cochrane database of systematic reviews. (5):Cd010383","DOI":"10.1002\/14651858.CD010383.pub2"},{"issue":"1","key":"1329_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y et al (2020) Overall survival with Osimertinib in untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 382(1):41\u201350","journal-title":"N Engl J Med"},{"issue":"25","key":"1329_CR6","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380\u20132388","journal-title":"N Engl J Med"},{"issue":"8","key":"1329_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735\u2013742","journal-title":"Lancet Oncol"},{"issue":"2","key":"1329_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213\u2013222","journal-title":"Lancet Oncol"},{"issue":"11","key":"1329_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","volume":"15","author":"G Recondo","year":"2018","unstructured":"Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L (2018) Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat reviews Clin Oncol 15(11):694\u2013708","journal-title":"Nat reviews Clin Oncol"},{"issue":"1","key":"1329_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY (2018) Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17(1):38","journal-title":"Mol Cancer"},{"issue":"19","key":"1329_CR11","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1016\/j.bmcl.2012.06.067","volume":"22","author":"S Hu","year":"2012","unstructured":"Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y et al (2012) Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Bioorg Med Chem Lett 22(19):6301\u20136305","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"1329_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.lungcan.2011.10.023","volume":"76","author":"F Tan","year":"2012","unstructured":"Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L et al (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung cancer (Amsterdam Netherlands) 76(2):177\u2013182","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"10","key":"1329_CR13","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","volume":"28","author":"YK Shi","year":"2017","unstructured":"Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP et al (2017) First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann Oncol 28(10):2443\u20132450","journal-title":"Ann Oncol"},{"issue":"10","key":"1329_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","volume":"14","author":"Y Shi","year":"2013","unstructured":"Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S et al (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14(10):953\u2013961","journal-title":"Lancet Oncol"},{"issue":"1","key":"1329_CR15","first-page":"90","volume":"25","author":"A Gu","year":"2013","unstructured":"Gu A, Shi C, Xiong L, Chu T, Pei J, Han B (2013) Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. Chin J cancer research = Chung-kuo yen cheng yen chiu 25(1):90\u201394","journal-title":"Chin J cancer research = Chung-kuo yen cheng yen chiu"},{"key":"1329_CR16","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2147\/OTT.S98363","volume":"9","author":"YW Shen","year":"2016","unstructured":"Shen YW, Zhang XM, Li ST, Lv M, Yang J, Wang F et al (2016) Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer. OncoTargets and therapy 9:929\u2013935","journal-title":"OncoTargets and therapy"},{"issue":"1","key":"1329_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.critrevonc.2012.09.006","volume":"86","author":"SD Mundle","year":"2013","unstructured":"Mundle SD, Marathe AS, Chelladurai M (2013) Transient therapy-related surge in serum tumor biomarkers: characterizing behavior and postulating its biologic role. Crit Rev Oncol\/Hematol 86(1):15\u201322","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"3","key":"1329_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D et al (2018) Association of the lung Immune Prognostic Index with Immune checkpoint inhibitor outcomes in patients with Advanced Non-Small Cell Lung Cancer. JAMA Oncol 4(3):351\u2013357","journal-title":"JAMA Oncol"},{"issue":"2","key":"1329_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/bjc.2015.200","volume":"113","author":"M Cummings","year":"2015","unstructured":"Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K et al (2015) Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br J Cancer 113(2):311\u2013320","journal-title":"Br J Cancer"},{"issue":"17","key":"1329_CR20","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.7150\/jca.44440","volume":"11","author":"BB Xu","year":"2020","unstructured":"Xu BB, Xu Y, Lu J, Wu Y, Wang JB, Lin JX et al (2020) Prognostic significance of combined lymphocyte-monocyte ratio and tumor-associated Macrophages in Gastric Cancer Patients after Radical Resection. J Cancer 11(17):5078\u20135087","journal-title":"J Cancer"},{"issue":"7","key":"1329_CR21","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.21037\/tlcr-21-267","volume":"10","author":"F Fu","year":"2021","unstructured":"Fu F, Deng C, Wen Z, Gao Z, Zhao Y, Han H et al (2021) Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. Translational lung cancer research 10(7):3144\u20133154","journal-title":"Translational lung cancer research"},{"issue":"3","key":"1329_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/SLA.0000000000003370","volume":"273","author":"G Jomrich","year":"2021","unstructured":"Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M et al (2021) High systemic Immune-Inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg 273(3):532\u2013541","journal-title":"Ann Surg"},{"issue":"23","key":"1329_CR23","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","volume":"20","author":"B Hu","year":"2014","unstructured":"Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W et al (2014) Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin cancer research: official J Am Association Cancer Res 20(23):6212\u20136222","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"1","key":"1329_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/SLA.0000000000002660","volume":"270","author":"MH Aziz","year":"2019","unstructured":"Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D et al (2019) The systemic-immune-inflammation index independently predicts survival and recurrence in Resectable Pancreatic Cancer and its Prognostic Value depends on bilirubin levels: a retrospective Multicenter Cohort Study. Ann Surg 270(1):139\u2013146","journal-title":"Ann Surg"},{"issue":"13","key":"1329_CR25","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1158\/1078-0432.CCR-19-3064","volume":"26","author":"X Li","year":"2020","unstructured":"Li X, Zhang L, Jiang D, Wang Y, Zang A, Ding C et al (2020) Routine-dose and high-dose Icotinib in patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR exon 21-L858R mutation: the Randomized, Phase II, INCREASE Trial. Clin cancer research: official J Am Association Cancer Res 26(13):3162\u20133171","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"1","key":"1329_CR26","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1038\/s41598-021-86203-4","volume":"11","author":"J Shi","year":"2021","unstructured":"Shi J, Li D, Liang D, He Y (2021) Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China. Sci Rep 11(1):6817","journal-title":"Sci Rep"},{"issue":"1","key":"1329_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cllc.2020.10.012","volume":"22","author":"SH Garrana","year":"2021","unstructured":"Garrana SH, Dagogo-Jack I, Cobb R, Kuo AH, Mendoza DP, Zhang EW et al (2021) Clinical and Imaging features of non-small-cell Lung Cancer in Young Patients. Clin Lung Cancer 22(1):23\u201331","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"1329_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J et al (2014) Metastatic sites and survival in lung cancer. Lung cancer (Amsterdam Netherlands) 86(1):78\u201384","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"1","key":"1329_CR29","first-page":"122","volume":"17","author":"JL Villano","year":"2015","unstructured":"Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG (2015) Incidence of brain metastasis at initial presentation of lung cancer. Neurooncology 17(1):122\u2013128","journal-title":"Neurooncology"},{"issue":"2","key":"1329_CR30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijrobp.2014.02.025","volume":"89","author":"Z Ji","year":"2014","unstructured":"Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q et al (2014) Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys 89(2):330\u2013337","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1329_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.suronc.2020.05.005","volume":"34","author":"X Xue","year":"2020","unstructured":"Xue X, Zang X, Liu Y, Lin D, Jiang T, Gao J et al (2020) Independent risk factors for lymph node metastasis in 2623 patients with non-small cell lung cancer. Surg Oncol 34:256\u2013260","journal-title":"Surg Oncol"},{"issue":"5","key":"1329_CR32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"key":"1329_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.10.012","volume":"139","author":"JC Thompson","year":"2020","unstructured":"Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y et al (2020) Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung cancer (Amsterdam Netherlands) 139:1\u20138","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"9","key":"1329_CR34","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G (1984) [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi 85(9):1001\u20131005","journal-title":"Nihon Geka Gakkai Zasshi"},{"issue":"11","key":"1329_CR35","doi-asserted-by":"publisher","first-page":"19655","DOI":"10.1002\/jcp.28565","volume":"234","author":"Y Xue","year":"2019","unstructured":"Xue Y, Zhou X, Xue L, Zhou R, Luo J (2019) The role of pretreatment prognostic nutritional index in esophageal cancer: a meta-analysis. J Cell Physiol 234(11):19655\u201319662","journal-title":"J Cell Physiol"},{"issue":"4","key":"1329_CR36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/SLA.0000000000002985","volume":"271","author":"K Okadome","year":"2020","unstructured":"Okadome K, Baba Y, Yagi T, Kiyozumi Y, Ishimoto T, Iwatsuki M et al (2020) Prognostic Nutritional Index, Tumor-infiltrating lymphocytes, and prognosis in patients with esophageal Cancer. Ann Surg 271(4):693\u2013700","journal-title":"Ann Surg"},{"issue":"13","key":"1329_CR37","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.7150\/jca.24889","volume":"9","author":"J Chi","year":"2018","unstructured":"Chi J, Xie Q, Jia J, Liu X, Sun J, Chen J et al (2018) Prognostic value of Albumin\/Globulin ratio in Survival and Lymph Node Metastasis in patients with Cancer: a systematic review and Meta-analysis. J Cancer 9(13):2341\u20132348","journal-title":"J Cancer"},{"key":"1329_CR38","doi-asserted-by":"crossref","unstructured":"Johannet P, Sawyers A, Qian Y, Kozloff S, Gulati N, Donnelly D et al (2020) Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer.J Immunother Cancer. ; 8(2)","DOI":"10.1136\/jitc-2020-001674"},{"key":"1329_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.bios.2018.08.060","volume":"123","author":"Y Gao","year":"2019","unstructured":"Gao Y, Huo W, Zhang L, Lian J, Tao W, Song C et al (2019) Multiplex measurement of twelve tumor markers using a GMR multi-biomarker immunoassay biosensor. Biosens Bioelectron 123:204\u2013210","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"1329_CR40","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jtho.2017.08.005","volume":"13","author":"SA Noonan","year":"2018","unstructured":"Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X et al (2018) Baseline and On-Treatment characteristics of serum tumor markers in Stage IV Oncogene-Addicted Adenocarcinoma of the lung. J Thorac oncology: official publication Int Association Study Lung Cancer 13(1):134\u2013138","journal-title":"J Thorac oncology: official publication Int Association Study Lung Cancer"},{"key":"1329_CR41","doi-asserted-by":"publisher","first-page":"645159","DOI":"10.3389\/fonc.2021.645159","volume":"11","author":"H Chen","year":"2021","unstructured":"Chen H, Fu F, Zhao Y, Wu H, Hu H, Sun Y et al (2021) The prognostic value of preoperative serum tumor markers in Non-Small Cell Lung Cancer varies with Radiological features and histological types. Front Oncol 11:645159","journal-title":"Front Oncol"},{"issue":"Suppl 17","key":"1329_CR42","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1002\/cncr.29568","volume":"121","author":"J Ni","year":"2015","unstructured":"Ni J, Liu DY, Hu B, Li C, Jiang J, Wang HP et al (2015) Relationship between icotinib hydrochloride exposure and clinical outcome in chinese patients with advanced non-small cell lung cancer. Cancer 121(Suppl 17):3146\u20133156","journal-title":"Cancer"},{"issue":"1","key":"1329_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13046-019-1133-z","volume":"38","author":"T Liu","year":"2019","unstructured":"Liu T, Jin L, Lu W, Gan H, Lin Z, Chen M et al (2019) Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo. J experimental Clin cancer research: CR 38(1):148","journal-title":"J experimental Clin cancer research: CR"},{"issue":"2","key":"1329_CR44","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/1759-7714.14261","volume":"13","author":"P Jiang","year":"2022","unstructured":"Jiang P, Zhang Y, Cui J, Wang X, Li Y (2022) Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs. Thorac cancer 13(2):257\u2013264","journal-title":"Thorac cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01329-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01329-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01329-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:37:12Z","timestamp":1687556232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01329-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1329"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01329-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"2 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Wuhan Union Hospital approved the study protocols and waived the need for informed consent due to the study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}